Risk factors affecting the therapeutic effect of onabotulinum toxin a on chronic migraine
This study confirms the real-world effectiveness of onabotulinumtoxinA in reducing headache frequency. Furthermore, patients with fibromyalgia may have a diminished likelihood of responding positively, underscoring the importance of personalized treatment strategies.
Authors
- Inês Mendes–Andrade (ORCID: https://orcid.org/0000-0002-3012-5467)
- Andreia Costa (ORCID: https://orcid.org/0000-0002-5331-9934)
- Beatriz Macêdo Medeiros (ORCID: https://orcid.org/0000-0003-3112-1473)
- Madalena Pinto (ORCID: https://orcid.org/0000-0002-4676-1409)
- Leonor Mendes-Andrade (ORCID: https://orcid.org/0009-0008-7951-0834)
Institutions
- Universidade do Porto (PT)
- Hospital do Divino Espírito Santo (PT)
- Centro de Medicina de Reabilitacao do Alcoitão (PT)
Publication Details
- Journal
- Pain Management
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1080/17581869.2025.2458448
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00